GSK begins patient enrollment in phase 3 study of GSK3511294 to treat severe eosinophilic asthma

GlaxoSmithKline plc announced that the first patient has been dosed in the SWIFT─2 trial as part of the phase 3 clinical programme investigating the safety and efficacy of GSK3511294 (GSK'294) in severe eosinophilic asthma (SEA).